.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,027,714

« Back to Dashboard

Claims for Patent: 6,027,714

Title: Formulation for inhalation
Abstract:A dry powder composition comprising budesonide and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.
Inventor(s): Trofast; Jan (Lund, SE)
Assignee: Astra Aktiebolag (SE)
Application Number:09/004,894
Patent Claims: 1. A dry powder pharmaceutical composition comprising budesonide and a carrier substance,

wherein both the budesonide and the carrier substance consist of particles having a mass median diameter of less than 10 .mu.m, and the composition has a poured bulk density of from 0.28 to 0.38 g/ml.

2. A composition according to claim 1 wherein the bulk density is from 0.30 to 0.36 g/ml.

3. A composition according to claim 1 wherein the active substance and carrier substance are substantially uniformly distributed.

4. A composition according to claim 1 for use in the treatment of a respiratory disorder.

5. A process for preparing a composition according to claim 1 which comprises

(a) micronising budesonide and the carrier substance;

(b) optionally conditioning the product; and

(c) spheronizing until the desired bulk density is obtained.

6. A process according to claim 5 which comprises a low energy remicronisation step after step (b).

7. A method of treating a patient suffering from a respiratory disorder which comprises administering to the patient a therapeutically effective amount of a composition according to claim 1.

8. A composition according to claim 1 wherein said carrier substance is selected from the group consisting of monosaccharides, disaccharides, polysaccharides and polyols.

9. A composition according to claim 1 wherein the carrier substance is selected from the group consisting of lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol and starch.

10. A composition according to claim 9 wherein said carrier substance is lactose monohydrate.

11. A composition according to claim 1 wherein the mass median diameter of the particles of budesonide and carrier is from 1 to 7 .mu.m.

12. A process according to claim 6, wherein the mass median diameter lies in the range of from 1 to 7 .mu.m.

13. A process according to claim 6, wherein the bulk density is from 0.30 to 0.36 g/ml.

14. A process according to claim 6, wherein the budesonide and the carrier substance are substantially uniformly distributed.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc